U. Kriemler-Krahn

发表

Phase I, open-label study of pasireotide in patients with BRAF-wild type and NRAS-wild type, unresectable and/or metastatic melanoma

D. Schadendorf, R. Dummer, O. Michielin, 2018, ESMO Open.

Improved Treatment Satisfaction and Convenience with Deferasirox in Iron-Overloaded Patients with β-Thalassemia: Results from the ESCALATOR Trial

A. Taher, A. El‐Beshlawy, Mohsen Saleh Elalfy, 2010, Acta Haematologica.

Long-term safety and efficacy of subcutaneous pasireotide in patients with Cushing’s disease: interim results from a long-term real-world evidence study

J. Schopohl, M. Roughton, K. Yuen, 2019, Pituitary.

Reduction in labile plasma iron during treatment with deferasirox, a once-daily oral iron chelator, in heavily iron-overloaded patients with β-thalassaemia

A. Taher, A. Pathare, A. Hmissi, 2009, European journal of haematology.

Multicenter Validation of Spin-Density Projection-Assisted R2-MRI for the Noninvasive Measurement of Liver Iron Concentration

Tim G St Pierre, Amal El-Beshlawy, Mohsen Elalfy, 2013, Magnetic resonance in medicine.

Achieving treatment goals of reducing or maintaining body iron burden with deferasirox in patients with β-thalassaemia: results from the ESCALATOR study

Amal El-Beshlawy, Abdullah Al Jefri, Kusai Al Zir, 2011, European journal of haematology.

Importance of optimal dosing ≥30 mg/kg/d during deferasirox treatment: 2.7-yr follow-up from the ESCALATOR study in patients with β-thalassaemia

Amal El-Beshlawy, Abdullah Al Jefri, Kusai Al Zir, 2011, European journal of haematology.

Efficacy and Safety of Deferasirox (Exjade®) in Preventing Cardiac Iron Overload in β-Thalassemia Patients with Normal Baseline Cardiac Iron: Results from the Cardiac Substudy of the EPIC Trial

D. Pennell, A. Taher, A. El‐Beshlawy, 2008 .

Efficacy and Safety of Once-Daily Oral Deferasirox (Exjade ® ) during a Median of 2.7 Years of Treatment in Heavily Iron-Overloaded Patients with β-Thalassemia

G. Damanhouri, A. Taher, A. El‐Beshlawy, 2008 .

Multicenter Validation of Spin-Density Projection-Assisted R2-MRI for the Non-Invasive Measurement of Liver Iron Concentration

A. Taher, A. El‐Beshlawy, Mohsen Saleh Elalfy, 2010 .

Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with β-thalassaemia: the ESCALATOR study

A. Taher, A. El‐Beshlawy, Mohsen Saleh Elalfy, 2009, European journal of haematology.

Long-term safety and efficacy of subcutaneous pasireotide in patients with Cushing’s disease: interim results from a long-term real-world evidence study

J. Schopohl, M. Roughton, K. Yuen, 2019, Pituitary.

Long-term safety and efficacy of subcutaneous pasireotide in Long-term safety and efficacy of subcutaneous pasireotide in patients with Cushing's disease: interim results from a long-term patients with Cushing's disease: interim results from a long-term real-world evidence study. real-world evidence

L. Tauchmanovà, U. Kriemler-Krahn, R. Maamari, 2022 .